Accepted answer
Start by asking what you are optimising for, because cost per milligram, documentation depth and lead time do not have a common winner.
Submitting to different laboratories introduces a method difference that commonly exceeds the supplier difference. Gradient slope alone can move a reported purity figure by a per cent in either direction.
Compare documentation on a fixed checklist rather than by impression: lot specificity, method section, chromatogram availability, quantified content, water and counter-ion figures, and whether the code is on the vial.
Content assay results across the published datasets vary considerably more between suppliers than purity does, which makes content the more discriminating axis.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Compare content, not purity. Purity clusters and content does not.